Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01720576 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT01720576 is a Phase 1 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 60 participants.
The verdict
NCT01720576, a Phase 1 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is a study to assess the safety and tolerability of subcutaneously administered REGN1033 (SAR391786) in healthy volunteers.
Interventions
- DRUG Placebo
- DRUG REGN1033 (SAR391786)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01720576
The ClinicalTrials.gov registry entry for NCT01720576 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01720576 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01720576 about?
NCT01720576 is a clinical study titled "Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)". This is a study to assess the safety and tolerability of subcutaneously administered REGN1033 (SAR391786) in healthy volunteers.
What is the current status of trial NCT01720576?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2012-10. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01720576?
The interventions under investigation include: Placebo (DRUG), REGN1033 (SAR391786) (DRUG).
Who is sponsoring clinical trial NCT01720576?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.